資源描述:
《壯骨膠囊治療絕經(jīng)后骨質(zhì)疏松癥的臨床觀察》由會(huì)員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。
1、黑龍江中醫(yī)藥大學(xué)碩士學(xué)位論文壯骨膠囊治療絕經(jīng)后骨質(zhì)疏松癥的臨床觀察姓名:陳超申請(qǐng)學(xué)位級(jí)別:碩士專業(yè):中西醫(yī)結(jié)合臨床指導(dǎo)教師:于雪峰2003.5.1黑龍江中醫(yī)藥大學(xué)碩士學(xué)位論文縮略語(yǔ)PMOP縮略語(yǔ)表英文中文PosemenopausalOsteoporosiS絕經(jīng)后骨質(zhì)疏松癥BMDBonemineraldensityEEstrogencAMP骨密度雌激素cycliCadenosinemonophosphate環(huán)磷酸腺苷TNFTumornecresiSfactorPTHParathyroidhormoneH
2、OPHydroxyprolineCTCaleitoninBGPBoneGlaproteinHRT腫瘤壞死因子甲狀旁腺激素羥脯氨酸降鈣素骨鈣素Hormonereplacementtherapy激素替代療法ERTEstrogenreplacementtherapy雌激素替代療法ILInterleukimePGProSta91andins白細(xì)胞介素前列腺素黑龍江中醫(yī)藥大學(xué)碩士學(xué)位論文中文摘要瀠質(zhì)疏松癥是指單位體積內(nèi)骨量減少,以致骨結(jié)構(gòu)改變,從而導(dǎo)致骨脆性增加甚至骨折的一類骨代謝性疾病。分為原發(fā)性骨質(zhì)疏松癥和
3、繼發(fā)性骨質(zhì)疏松癥,絕經(jīng)后骨質(zhì)疏松癥(PMOP)屬于原發(fā)性骨質(zhì)疏松癥,是機(jī)體自然衰退、老化過(guò)程的組成部分。尤其多發(fā)于絕經(jīng)2年以上、年齡70歲以下的婦女。據(jù)流行病學(xué)調(diào)查顯示,該病在亞洲和拉丁美洲的發(fā)病率最高。絕經(jīng)后骨質(zhì)疏松癥已成為威脅人類健康的一大疾病。{本研究旨在觀察壯骨膠囊治療絕經(jīng)后骨質(zhì)疏松癥的臨床療效。將50例絕經(jīng)后骨質(zhì)疏松癥患者作為觀察對(duì)象,隨機(jī)分為治療組、對(duì)照組,每組Z5例,治療組給予壯骨膠囊治療,對(duì)照組給予倍美力治療,共服藥6個(gè)月,觀察療前、療后的臨床癥狀、體征及血E。、ALP、Ca:尿Ca/
4、Or,尿HOP/Cr和骨密度的變化。結(jié)果表明:治療組總有效率為90.9%,對(duì)照組總有效率為80%,兩組療效無(wú)顯著差異(P>O.05);治療組各指標(biāo)療后均比療前有顯著差異(P<0.01)。壯骨膠囊無(wú)不良反應(yīng)及毒副作用。我們認(rèn)為絕經(jīng)后骨質(zhì)疏松癥以腎虛、脾虛、血瘀為主,多伴有肝郁,所以,可以補(bǔ)腎健脾,活血舒肝為治療原則。壯骨膠囊依據(jù)此法立方,在治療絕經(jīng)后骨質(zhì)疏松癥上是一種臨床有效的藥物。關(guān)鍵詞:絕經(jīng)后骨質(zhì)疏松癥j壯骨膠囊1臨床觀察義中醫(yī)中藥治療,黑龍江中醫(yī)藥大學(xué)碩士學(xué)位論文ABSTRAOTOsteoporo
5、SiSiSakindofmetabolismdiSeaseofSkeletalsyStem,thecharacterofthiSdiSeaseiSbonevolume’sreduce,boneStructure’salternatiOn,bonefragi1ity’sincreaseingandfracture.PosemenopausalOsteoporosiSiSapartofbodydiminutionproCess.PMOPalwaySoccuresinthePeriodof2yearslat
6、eraftermenopauseandOnwhoiSunder70.InveStigationofepidemi0109ydisplaythatPMOP’SinCi—dencerateiShigheStinAsianandLatinAmerica.ThepurposeofthiSobservationiSt0observetheC1inicalCurativeeffectofZhuanggucapSUle.50PMOPpatientswererandomlYdiVidedintoZhuangguCap
7、sulegroupandPremarinTabletgroup.TheZhuangguCapsulegrouptakeZhuangguCapsulefor6mortths.PremarinTabletgrouptakeBeimeilifor6months.WeoberveBMD,E2,ALP,HOP/Cr,Ca/Orbeforeandafterthetreatment.TheresultiSthatZhuangguCapsulecanobviOUSlYincregsebonedensitv.There
8、iSnOobviOUslYdifferencebetweenZhuangguCapsulegroupandPremarinTabletgroupincurativeeffectintrearingPMOP.Invigoratingthekidneyandspleen.a(chǎn)ctivatingthebloodcirculationandrelievingthe1ivetshouldbeabasiCDricipleintreatingPMOP.ZhuangguC